The acquisition marks the company’s strategic entry into the fast-growing Hormone Replacement Therapy (HRT) segment and significantly strengthens its gynaecology portfolio in India
In collaboration with the Soham Foundation, the initiative focused on perimenopause, menopause, and hormone replacement therapy awareness at BESCOM’s Bengaluru headquarters.
The recommendation covers FYLREVY 14.2 mg and 18.9 mg for non-hysterectomised postmenopausal women experiencing oestrogen deficiency symptoms at least 12 months after their last menses
The FDA is initiating removal of the boxed warnings following a comprehensive review of the scientific literature
Pete Pharma will leverage FABRX’s extensive foundation of scientific validation to deliver a commercially viable, pharmacy-ready solution in the US
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
